復星醫藥(600196.SH)一季度淨利潤升46.78%至8.47億元
格隆匯 4 月 26日丨復星醫藥(600196.SH)發佈2021年第一季度報吿,實現營業收入80.56億元,同比增長37%;歸屬於上市公司股東的淨利潤8.47億元,同比增長46.78%;歸屬於上市公司股東的扣除非經常性損益的淨利潤6.58億元,同比增長50.76%;基本每股收益0.33元。
主要系:1)新品和次新品漢利康(利妥昔單抗注射液)、蘇可欣(馬來酸阿伐曲泊帕片)、漢曲優(注射用曲妥珠單抗)等的貢獻;2)上年同期收入利潤均受疫情因素影響,報吿期內收入利潤取得恢復性增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.